BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2023

Primary Completion Date

July 14, 2025

Study Completion Date

July 14, 2026

Conditions

Multiple Myeloma in Relapse

Interventions

BIOLOGICAL

BCMA-GPRC5D CAR-T cells

patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg

Trial Locations (1)

RECRUITING

Shenzhen University General Hospital, Shenzhen

All Listed Sponsors

lead

Shenzhen University General Hospital

OTHER